RadiaDyne
RadiaDyne Announces First Commercial Sale Milestone Of Their OARtrac Patient Dose Monitoring System To Leading Cancer Center

HOUSTON, Jan. 30, 2018 /PRNewswire/ -- RadiaDyne announces the first commercial sale in New York City, New York of their upcoming OARtrac system to one of the recognized leaders in radiation delivery for cancer treatment. "We are excited about the early interest and momentum of this new technology, and the industry's recognition of the OARtrac® system's capabilities to provide the best clinical solution for monitoring treatment dose," said Bret Boudousquie, RadiaDyne's President. "These early clinical adopters are leading the way for other centers seeking innovative technology for improved outcomes in cancer treatment. It is exciting to see early orders even prior to the official clinical launch of the technology," said John Isham, RadiaDyne's Founder and CEO.

ABOUT OARTRAC:
OARtrac® is the first of its kind patient radiation dose monitoring system which provides gold standard accuracy, real-time pinpoint measurement, and proprietary intracavitary delivery devices to physically measure radiation dose during photon external beam therapy and HDR brachytherapy radiation treatments. OARtrac® provides critical radiation dose feedback which helps facilitate adaptive radiotherapy for true personalized treatment with the goal to reduce side effects and offer better clinical outcomes.

ABOUT RADIADYNE:
RadiaDyne is a privately held medical diagnostic and device company focused on patient dose monitoring technology to improve cancer treatment outcomes. RadiaDyne designs and innovates specialized sensor technology and treatment devices which assist Radiation Oncologists in delivering radiation dose to the cancerous targets, while minimizing damage to the surrounding healthy tissue. RadiaDyne is the pioneer in developing and offering real-time patient dose monitoring systems through their patented OARtrac® system.

MEDIA CONTACT
Oscar Calero
pr@radiadyne.com

RadiaDyne